Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
CDK inhibitors
Pharma
Novartis pressures Lilly with Kisqali's broad breast cancer nod
The expanded label separates Novartis' Kisqali from Eli Lilly's Verzenio by covering patients who don't have cancer cells in their lymph nodes.
Angus Liu
Sep 17, 2024 3:04pm
ASCO: Lilly seeks prostate cancer redemption after Verzenio flop
May 23, 2024 5:00pm
SABCS: Novartis gives update on Kisqali in early breast cancer
Dec 8, 2023 9:15am
Lilly's Verzenio barely misses overall survival goal in 1L
Dec 6, 2023 10:00am
AstraZeneca, BeiGene, Coherus—Fierce Pharma Asia
Dec 1, 2023 8:34am
Eyeing Lilly, Novartis touts broader adjuvant breast cancer win
Mar 27, 2023 11:20am
